Acute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers

Psychopharmacology

Volumn 211, Issue 3, 2010, Pages 303-312

  Duke, Angela N ^a   Correia, Christopher J ^a,b   Walsh, Sharon L ^a,c   Bigelow, George E ^a   Strain, Eric C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AUBURN UNIVERSITY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Buprenorphine; Buprenorphine naloxone; Human; Non dependent; Opioid

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; HYDROMORPHONE; NARCOTIC ANALGESIC AGENT; PLACEBO; DRUG COMBINATION; NALOXONE;

ADULT; ARTICLE; BODY TEMPERATURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; FEMALE; HUMAN; MALE; OXYGEN SATURATION; PRIORITY JOURNAL; PULSE RATE; PUPIL; SUBSTANCE ABUSE; SYSTOLIC BLOOD PRESSURE; VISUAL ANALOG SCALE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG COMBINATION; DRUG USE; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; OPIOID-RELATED DISORDERS; PSYCHOLOGY; QUESTIONNAIRE; SUBLINGUAL DRUG ADMINISTRATION;

ADMINISTRATION, SUBLINGUAL; ADULT; BUPRENORPHINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG USERS; FEMALE; HUMANS; HYDROMORPHONE; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NALOXONE; OPIOID-RELATED DISORDERS; QUESTIONNAIRES;

EID: 77955466653     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-010-1898-4     Document Type: Article

References (37)

1. H Alho D Sinclair E Vuori A Holopainen 2007 Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users Drug Alcohol Depend 88 75 78 10.1016/j.drugalcdep.2006.09.012 1:CAS:528:DC%2BD2sXjtVans70%3D 17055191 (Pubitemid 46400304)
2. RE Bullingham HJ McQuay D Dwyer MC Allen RA Moore 1981 Sublingual buprenorphine used postoperatively: clinical observations and preliminary pharmacokinetic analysis Br J Clin Pharmacol 12 117 122 1:STN:280: DyaL38%2FmvVyktg%3D%3D 7306425
3. CN Chiang RL Hawks 2003 Pharmacokinetics of the combination tablet of buprenorphine and naloxone Drug Alcohol Depend 70 S39 S47 10.1016/S0376-8716(03) 00058-9 1:CAS:528:DC%2BD3sXjsVWlu7s%3D 12738349 (Pubitemid 36556059)
4. SD Comer ED Collins 2002 Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers J Pharmacol Exp Ther 303 695 703 10.1124/jpet.102.038141 1:CAS:528:DC%2BD38XotlCnsrY%3D 12388653 (Pubitemid 35231243)
5. A Cowan JW Lewis IR MacFarlane 1977 Agonist and antagonist properties of buprenorphine: a new antinociceptive agent Br J Pharmacol 60 537 545 1:CAS:528:DyaE2sXlvFertbc%3D 409448
6. JE Dum A Herz 1981 In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonist and antagonistic actions Br J Pharmacol 74 627 633 1:CAS:528:DyaL38XhtFGrsrs%3D 6271322
7. HG Fraser GD van Horn WR Marin AB Wolbach H Isbell 1961 Methods for evaluating addiction liability. (A) "Attitude" of opiate addicts toward opiate-like drugs, (B) A short-term "direct" addiction test J Pharmacol Exp Ther 133 371 387 1:CAS:528:DyaF3MXhsVGltL4%3D 13701509
8. PJ Fudala E Yu W Macfadden C Boardman CN Chiang 1998 Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts Drug Alcohol Depend 50 1 8 10.1016/S0376-8716(98)00008-8 1:CAS:528:DyaK1cXitVKku7k%3D 9589267 (Pubitemid 28176605)
9. DS Harris RT Jones S Welm RA Upton E Lin J Mendelson 2000 Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine Drug Alcohol Depend 61 85 94 10.1016/S0376-8716(00) 00126-5 1:CAS:528:DC%2BD3cXovFaqt7Y%3D 11064186
10. Jasinski DR (1977) Assessment of the abuse potentiality of morphinelike drugs (methods used in man). In: Martin WR (ed) Drug addiction I. Springer, Berlin, pp 197-258
11. DR Jasinski JS Pevnick JD Griffith 1978 Human pharmacology and abuse potential of the analgesic buprenorphine Arch Gen Psychiatry 35 501 516 1:CAS:528:DyaE1cXktFOitbw%3D 215096
12. DR Jasinski PJ Fudala RE Johnson 1989 Sublingual versus subcutaneous buprenorphine in opiate abusers Clin Pharmacol Ther 45 513 519 1:CAS:528:DyaL1MXksFShtLk%3D 2721107
13. RE Johnson JH Jaffe PJ Fudala 1992 A controlled trial of buprenorphine treatment for opioid dependence Arch Gen Psychiatry 35 501 516
14. RE Johnson MA Chutuape EC Strain SL Walsh ML Stitzer GE Bigelow 2000 A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence N Engl J Med 343 1290 1297 10.1056/NEJM200011023431802 1:CAS:528:DC%2BD3cXotV2iurg%3D 11058673
15. RE Johnson EC Strain L Amass 2003 Buprenorphine: how to use it right Drug Alcohol Depend 70 S59 S77 10.1016/S0376-8716(03)00060-7 1:CAS:528: DC%2BD3sXjsVWlu7c%3D 12738351 (Pubitemid 36556061)
16. HE Jones GE Bigelow KL Preston 1999 Assessment of opioid partial agonist activity with the three-choice hydromorphone dose-discrimination procedure J Pharmacol Exp Ther 289 1350 1361 1:CAS:528:DyaK1MXjtlGns7k%3D 10336526
17. JW Lewis 1985 Buprenorphine Drug Alcohol Depend 14 363 372 10.1016/0376-8716(85)90067-5 1:CAS:528:DyaL2MXkvVWis7c%3D 2986930 (Pubitemid 15149057)
18. W Ling C Charuvastra JF Collins S Batki LS Brown Jr P Kintaudi DR Wesson L McNicholas DJ Tusel U Malkerneker JA Renner Jr E Santos P Casandonte C Fye S Stine RI Wang D Segal 1998 Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial Addiction 93 475 486 10.1046/j.1360-0443.1998.9344753.x 1:STN:280:DyaK1czkvFSisw%3D%3D 9684386
19. K Lutfy S Eitan CD Bryant YC Yang N Saliminejad W Walwyn BL Kieffer H Takeshima FI Carroll NT Maidment CJ Evans 2003 Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors J Neurosci 23 10331 10337 1:CAS:528:DC%2BD3sXpt1ylurY%3D 14614092
20. J Mendelson RT Jones 2003 Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment? Drug Alcohol Depend 70 S29 S37 10.1016/S0376-8716(03)00057-7 1:CAS:528: DC%2BD3sXjsVWlu7w%3D 12738348 (Pubitemid 36556058)
21. J Mendelson RT Jones I Fernandez S Welm AK Melby MJ Baggott 1996 Buprenorphine and naloxone interactions in opiate-dependent volunteers Clin Pharmacol Ther 60 105 114 10.1016/S0009-9236(96)90173-3 1:CAS:528: DyaK28XltFSqu7c%3D 8689806
22. J Mendelson RT Jones S Welm J Brown SL Batki 1997 Buprenorphine and naloxone interactions in methadone maintenance patients Biol Pshcyiatry 41 1095 1101 10.1016/S0006-3223(96)00266-1 1:CAS:528:DyaK2sXjsFShs7k%3D (Pubitemid 27240004)
23. J Mendelson RA Upton ET Everhart P Jacob RT Jones 1997 Bioavailability of sublingual buprenorphine J Clin Pharmacol 37 31 37 10.1177/009127009703700106 1:CAS:528:DyaK2sXhvFKgsbg%3D 9048270
24. J Mendelson RT Jones S Welm M Baggott I Fernandez AK Melby RP Nath 1999 Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers Psychopharmacology 141 37 46 10.1007/s002130050804 1:CAS:528:DyaK1MXhtFygu78%3D 9952063 (Pubitemid 29193293)
25. KL Preston GE Bigelow 2000 Effects of agonist-antagonist opioids in humans trained in a hydromorphone/not hydromorphone discrimination J Pharmacol Exp Ther 295 114 124 1:CAS:528:DC%2BD3cXnt1ygtbk%3D 10991968
26. KL Preston GE Bigelow IA Liebson 1988 Buprenorphine and naloxone alone and in combination in opioid-dependent human volunteers Psychopharmacology 94 484 490 10.1007/BF00212842 1:CAS:528:DyaL1cXhvFygsr0%3D 2453895
27. KL Preston GE Bigelow IA Liebson 1990 Effects of sublingually given naloxone in opioid-dependent human volunteers Drug Alcohol Depend 25 27 34 10.1016/0376-8716(90)90136-3 1:CAS:528:DyaK3cXhvFWrs70%3D 2323306 (Pubitemid 20086950)
28. J Rosado SL Walsh GE Bigelow EC Strain 2007 Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100 mg of daily methadone Drug Alcohol Depend 90 261 269 10.1016/j.drugalcdep.2007.04. 006 1:CAS:528:DC%2BD2sXpsFGktL0%3D 17517480 (Pubitemid 47287716)
29. RS Schottenfeld JR Pakes A Oliveto D Ziedonis TR Kosten 1997 Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse Arch Gen Psychiatry 54 713 720 1:CAS:528: DyaK2sXls1ygtrY%3D 9283506
30. KB Stoller GE Bigelow SL Walsh EC Strain 2001 Effects of buprenorphine/naloxone in opioid dependent humans Psychopharmacology 154 230 242 10.1007/s002130000637 1:CAS:528:DC%2BD3MXjsVens70%3D 11351930 (Pubitemid 32247184)
31. EC Strain KL Preston IA Liebson GE Bigelow 1993 Precipitated withdrawal by pentazocine in methadone-maintained volunteers J Pharmacol Exp Ther 267 624 634 1:CAS:528:DyaK2cXksFyjuw%3D%3D 7504098
32. EC Strain ML Stitzer IA Liebson GE Bigelow 1994 Comparison of buprenorphine and methadone in the treatment of opioid dependence Am J Psychiatry 151 7 1025 1030 1:STN:280:DyaK2c3nvFOhsA%3D%3D 8010359
33. EC Strain K Stoller SL Walsh GE Bigelow 2000 Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers Psychopharmacology 148 347 383 10.1007/s002130050066
34. EC Strain DE Moody KB Stoller SL Walsh GE Bigelow 2004 Relative bioavailability of different buprenorphine formulations under chronic dosing conditions Drug Alcohol Depend 74 37 43 10.1016/j.drugalcdep.2003.11.008 1:CAS:528:DC%2BD2cXjtV2ns7k%3D 15072805 (Pubitemid 38457051)
35. SL Walsh EC Strain ME Abreu GE Bigelow 2001 Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans Psychopharmacology 157 151 162 10.1007/s002130100788 1:CAS:528: DC%2BD3MXns1Clt7w%3D 11594439 (Pubitemid 32802126)
36. DS Weinberg CE Inturrisi B Reidenberg DE Moulin TJ Nip S Wallenstein RW Houde KM Foley 1988 Sublingual absorption of select opioid analgesics Clin Pharmacol Ther 44 335 342 1:CAS:528:DyaL1cXlvVaqu7g%3D 2458208
37. LL Weinhold KL Preston M Farre IA Liebson GE Bigelow 1992 Buprenorphine alone and in combination with naloxone in non-dependent humans Drug Alcohol Depend 30 263 274 10.1016/0376-8716(92)90061-G 1:STN:280:DyaK3s%2FhtVektw%3D%3D 1396108